Finance

Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.

Researchers find that a thorough evaluation of drug spending and value can lead to a better allocation of healthcare resources.

Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.

BioNTech will invest $200 million and get access to Autolus’ manufacturing sites.

The $1.3 billion acquisition—which included two aqua manufacturing plants—expands Merck’s portfolio in the veterinary pharma space.

Novartis rescinds rights to to develop and commercialize multi-tyrosine kinase inhibitor dovitinib due to a material breach by Allarity for lack of financial payment.

The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.

There’s reason to believe that a positive pivot may be in the offing.

Express Scripts has announced plans to offer to a new pharmacy network cost-based pricing option for prescription medications and pharmacy services.

Could the sector please get a little ‘rate’ relief?

Payers won’t let these products break the bank.

When you know it is coming—but it takes forever to get there.

Strong economic data in other sectors mean rising ‘real’ rates.

Could the sector be nearing a turning point in performance?

New executive brings over 30 years of experience in the biopharma industry.

But will Washington’s dealmaking stance upend the momentum?

Conditions require a disciplined approach to drug pricing.

The Medicare Part D cap won’t solve need for financial assistance.

Such a scenario is one possibility as the bear market languishes on.

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

The ‘blistering’ pace may further divide the haves from the have-nots.

Over two years into a bear market, it still can’t catch a sustainable bid.

Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.